In May 2014, AstraZeneca announced that it was seeking a partner for its experimental Alzheimer’s drug, the oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293. Now, Eli Lilly has stepped up to help move the drug through Phase II and III trials (1). AstraZeneca previously highlighted the potential revenue from the drug at $5 billion per annum during Pfizer’s unsuccessful takeover bid in May 2014. However, they gave it only a 9 percent chance of success.

Read the full article now Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be! Login Email Password Forgot your password? Keep me logged in Log in Or register now - it’s free and always will be! You will benefit from: Unlimited access to ALL articles

News, interviews & opinions from leading industry experts

Receive print (and PDF) copies of The Medicine Maker magazine Register Or Login via Social Media Twitter By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Charlotte Barker

As an Editor at Texere, I’m working closely with our audience to create vibrant, engaging content that reflects the hard work and passion that goes into bringing new medicines to market. I got my start in biomedical publishing as a commissioning editor for healthcare journals and have spent my career covering everything from early-stage research to clinical medicine, so I know my way around. And I can’t think of a more interesting, challenging or important area to be working in.